ESSA Pharma

ESSA Pharma EBITDA

Delisted

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of ESSA Pharma (EPIX) as of Oct 24, 2026 is -34.42 M USD. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was -32.14 M USD — a change of 7.09% (lower).

EBITDA

-34.42 MUSD

YoY

7.09%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of ESSA Pharma is 2024 -34.42 M USD. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of ESSA Pharma was 2023 -32.14 M USD. It decreases by 7.09% lower compared to the previous year.

The ESSA Pharma EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2017
-16.01 M USD
Jan 1, 2018
-11.00 M USD
Jan 1, 2019
-12.15 M USD
Jan 1, 2020
-23.93 M USD
Jan 1, 2021
-37.16 M USD
Jan 1, 2022
-36.97 M USD
Jan 1, 2023
-32.14 M USD
Jan 1, 2024
-34.42 M USD
The ESSA Pharma EBITDA history
YEAREBITDAYoY
-34.42 MUSD+7.09%
-32.14 MUSD-13.06%
-36.97 MUSD-0.51%
-37.16 MUSD+55.29%
-23.93 MUSD+96.95%
-12.15 MUSD+10.45%
-11.00 MUSD-31.29%
-16.01 MUSD-14.06%
-18.63 MUSD+17.91%
-15.80 MUSD+441.10%
-2.92 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

ESSA Pharma Stock analysis

What does ESSA Pharma do? ESSA Pharma Inc is a biopharmaceutical company specializing in the development of therapies for the treatment of prostate cancer and other types of cancer. The company is headquartered in Vancouver, Canada and was founded in 2009. The history of ESSA Pharma Inc begins with the discovery of a new approach to treating prostate cancer by the company's founders. They discovered that a combination of an androgen receptor inhibitor and a NEDDylation signaling inhibitor could offer a new and effective approach to treating prostate cancer. Based on this discovery, they founded ESSA Pharma Inc to further develop this therapy. ESSA Pharma Inc's business model is based on the discovery, development, and commercialization of therapies for the treatment of prostate cancer and other types of cancer. The company has a pipeline of products in various clinical phases aimed at effectively combating prostate cancer and other types of cancer. ESSA Pharma Inc operates in two main divisions: research and development, and marketing and sales. The company's research and development department is dedicated to identifying and developing new compounds tailored to the specific needs of patients with prostate cancer. The company also works closely with researchers and physicians to test the efficacy of its products in treatment protocols and clinical practice. The second division of ESSA Pharma Inc deals with the marketing and sales of its products. Here, the company works closely with pharmaceutical manufacturers and other companies to market and sell its products worldwide. The company also has its own sales department that serves customers worldwide. ESSA Pharma Inc currently offers several products in different stages of clinical trials. These include EPI-506, an androgen receptor inhibitor currently being used in a Phase 1 study for the treatment of prostate cancer, and EPI-7386, a NEDDylation signaling inhibitor currently in a Phase 1 study for the treatment of prostate cancer. In addition, ESSA Pharma Inc has formed partnerships with other companies to further develop its technology platform and pipeline of cancer therapies. For example, the company is collaborating with Bayer Healthcare to advance the development of EPI-7386. Overall, ESSA Pharma Inc is an innovative and emerging biotech company focused on the development of therapies for the treatment of prostate cancer and other types of cancer. The company is pursuing an ambitious strategy and has already achieved promising results in the development of new compounds for the treatment of prostate cancer. ESSA Pharma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ESSA Pharma stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of ESSA Pharma is -34.42 M USD in 2024.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of ESSA Pharma changed from -32.14 M USD to -34.42 M USD, representing a 7.09% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) ESSA Pharma since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s ESSA Pharma historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — ESSA Pharma

All Key Metrics — ESSA Pharma